공시 • Jun 20
Theraclion Announces Board Changes Theraclion announced that Yann Duchesne decided not to stand for re-election as Director and Chairman of the Board following the General Meeting held on June 18, 2026, positions he had held since January 24, 2022. Following the General Meeting held on June 18, 2026, the shareholders appointed a new Board of Directors composed of Lijuan Deng, Claude Lenoir, Cédric Bellanger, Mehdi El Glaoui and Vincent Gardès, the latter joining the Board of Directors of Theraclion after having served as an observer over recent months. The new Board of Directors subsequently appointed Claude Lenoir as Interim Chairman of the Board of Directors, with immediate effect. Yann Duchesne is an experienced French business leader and former Managing Partner of McKinsey & Company France. He has advised numerous major French and international companies on growth, transformation and organizational strategy. He subsequently held responsibilities in private equity in London, before serving in senior executive roles in industry. Over the past twenty years, he has served on numerous boards of directors of listed and private equity-backed companies, often as Chairman. Claude Lenoir is an experienced executive in the MedTech sector, with a career distinguished by leading international medical device and diagnostics companies. He notably served as CEO of Echosens from 2013 to 2018, during which the company continued its international development around FibroScan and non-invasive liver disease diagnostics. He also led Air Liquide Medical Systems, reinforcing his profile as an executive specialising in medical technologies and healthcare equipment and their international commercial deployment. Since 2023, he has been a member of the Board of Directors of Theraclion, where he contributes his experience in MedTech growth, internationalisation, governance and the transition of innovative medical technology toward broad market adoption. Vincent Gardès is an experienced MedTech executive, recognised for his role in the international development of innovative companies, particularly in the United States. A former leader of Vexim, which he guided through its growth to its acquisition by Stryker, he also held management positions at Germitec, contributing to its organisational development and commercial growth. He is currently CEO of Amber Implants, with a key role in its commercialisation phase and US expansion. His background brings strong expertise in international strategy, US market access, commercial structuring and value creation in innovative medical devices. 공시 • Jun 09
Theraclion Secures AMA CPT Editorial Panel Approval For New Category III CPT Code For Sonovein Theraclion announced that the American Medical Association CPT Editorial Panel has approved the creation of a new Category III CPT code for non-invasive high intensity focused ultrasound (HIFU) treatment of varicose veins, performed using Sonovein. The new code will become effective on January 1, 2027. Category III CPT codes are designed for emerging medical technologies, services and procedures. They provide a standardized mechanism to report procedures, track utilization, collect clinical data and support evidence development. This new code will support future engagement with healthcare providers, payers and clinical investigators as Theraclion prepares for the potential U.S. commercialization of Sonovein. In parallel to the reimbursement pathway effort, the Sonovein market approval application was submitted to the FDA in December 2025 via the De Novo pathway, following a pivotal study demonstrating 96.8% efficacy. Discussions with the FDA are progressing constructively as part of the review process with exchanges underway, and a decision is now expected toward the end of the Third Quarter or the beginning of the Fourth Quarter 2026. Theraclion continues to execute its U.S. market entry plan, with commercial launch preparations advancing toward a targeted launch by year-end 2026. The AMA CPT Editorial Panel’s actions do not constitute endorsement of any specific technology or guarantee reimbursement coverage or payment. Payment, coverage, and coding policies remain subject to individual payer determination. 공시 • Jun 03
Theraclion Presents Promising Preliminary Results From Sonovein SpeedPulse At First International HIFU Congress Theraclion announced the success of the first international HIFU congress, held in Parma on May 22 and 23, 2026, during which promising preliminary results from the clinical study conducted in Prague with its next-generation Sonovein SpeedPulse were presented. The Third International Days of Phlebology congress, held in Parma, Italy, on May 22 and 23, 2026, and presented as the first HIFU congress, allowed the company to present its Sonovein technology to the international phlebology community. Dedicated HIFU sessions and roundtable discussions were organized during the congress, during which 13 Sonovein users and key opinion leaders shared routine clinical practice results, covering hundreds of patients, different types of veins and several years of follow-up. More than one hundred healthcare professionals visited Theraclion’s booth during the congress, confirming the growing interest of the scientific community in the potential of non-invasive HIFU treatment enabled by Sonovein. During this event, preliminary results from the SpeedPulse study, initiated and conducted by Professor Jaroslav Strejcek in Prague, were presented. This study aims to evaluate a new prototype integrating advanced acoustic and robotic technologies designed to significantly accelerate treatment delivery and make the device easier to use. Early observations show a major reduction in procedure duration, with treatments now performed in less than 30 minutes, together with improved physician ergonomics enabled by enhanced robotic range of motion and additional degrees of freedom. These advances address a key adoption challenge: making treatment faster, simpler and easier to integrate into daily practice. Theraclion emphasizes that the current prototype remains under clinical evaluation and is not yet commercially available. Additional development work and regulatory approvals will be required before any potential market introduction. 공시 • May 19
Theraclion SA, Annual General Meeting, Jun 18, 2026 Theraclion SA, Annual General Meeting, Jun 18, 2026. Location: 240 avenue pierre brossolette, malakoff France 공시 • Apr 22
Theraclion SA has filed a Follow-on Equity Offering in the amount of €5.992544 million. Theraclion SA has filed a Follow-on Equity Offering in the amount of €5.992544 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 12,484,467
Price\Range: €0.48
Security Features: Attached Warrants
Transaction Features: Rights Offering 공시 • Jan 30
Theraclion SA to Report Fiscal Year 2025 Results on Apr 16, 2026 Theraclion SA announced that they will report fiscal year 2025 results at 5:40 PM, Central European Standard Time on Apr 16, 2026 
